News Archive

October 2019

• Ad-hoc Releases Oct 30, 2019

  Novartis announces AVXS-101 intrathecal study update

  FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal studyAdverse events that might be expected from the pre-clinical…
• Press Release Oct 24, 2019

  Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis

  New Cosentyx® (secukinumab) label to include 300 mg up-titration option is informed by results from the Phase III MEASURE 3 study[1] Approval provides clinicians with greater choice for their…
• Ad-hoc Releases Oct 22, 2019

  Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US

  Continuing operations2 net sales up 13% (cc1, +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regionsEntresto USD 430 million (+61% cc…
• Ad-hoc Releases Oct 22, 2019

  Novartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-Einführung von Beovu

  Der Nettoumsatz der fortzuführenden Geschäftsbereiche2 steigt aufgrund folgender Beiträge um 13% (kWk1, +10% USD): Cosentyx erzielt einen Umsatz von USD 937 Millionen (+27% kWk)…
• Ad-hoc Releases Oct 22, 2019

  Novartis, encore un fort trimestre: croissance à deux chiffres des ventes et expansion de la marge core1; hausse des prévisions de chiffre d’affaires et de résultat en 2019; Beovu lancé aux USA

  Chiffre d’affaires net des activités poursuivies2 en hausse de 13% (tcc1, +10% USD) soutenu par: Cosentyx: USD 937 millions (+27% tcc), avec une forte demande dans toutes les indications et…
• Press Release Oct 16, 2019

  Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease

  REACH2 trial results confirm Jakavi significantly improves overall response rate (ORR) at 28 days vs. best available therapy in steroid-refractory acute graft-versus-host disease (GvHD)[1] GvHD…
• Press Release Oct 10, 2019

  Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis

  New two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results…
• Press Release Oct 09, 2019

  Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practice

  Data from five real-world evidence (RWE) and observational studies being conducted in North America, Latin America and Europe provide extensive cumulative insights for Cosentyx (secukinumab) clinical…
• Press Release Oct 08, 2019

  Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg

  Results from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair’s dose (…
• Ad-hoc Releases Oct 08, 2019

  Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

   In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
• Press Release Oct 05, 2019

  AveXis presents updated STRONG data at WMS

  Older patients (≥ 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follow-up…
• Ad-hoc Releases Oct 02, 2019

  Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum

  Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission…